Thyroid Stimulating Hormone as a Possible Additional COVID-19 Outcome Marker DOI Creative Commons
Vrkljan Anamarija Zrilic, Ana Majić,

Tanja Režić Palaversa

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(2), P. 314 - 314

Published: Feb. 12, 2024

Background and Objectives: The interaction between thyroid SARS-CoV-2 is complex not yet fully understood. This study aimed to identify a predictive value of serum TSH levels on the short-term middle-term outcomes patients hospitalized for COVID-19. Materials Methods: We retrospectively analyzed electronic records (ERs) data COVID-19 March 2020 June 2021 their ERs during outpatient visits, 6–8 weeks post-discharge, in cases known no previous disorder. (length hospital stay, MSCT findings lung involvement, required level oxygen supplementation, admission ICU, death) after 6 8 post-discharge (MSCT involvement) were analyzed. Results: There 580 included: 302 males 278 females, average age 66.39 ± 13.31 years, with disease (TSH mean 1.16 1.8; median 0.80; higher than 6.0 mIU/L included). Higher was observed less severe associated significantly SpO2 hospitalization. Patients who overall more supplementation or HFOT, mechanical ventilation, frequently admitted ICU often treated corticosteroids had lower those did show these indicators severity. Lower also present non-survivors when compared survivors (all p < 0.01). low hospitalization persistent involvement post-COVID-19 period (p = 0.028). In period, there an overall, statistically significant increase 0.001). Conclusions: Low/suppressed acute may be additional laboratory test that should included prediction unfavorable short- outcomes.

Language: Английский

Thyroid Stimulating Hormone as a Possible Additional COVID-19 Outcome Marker DOI Creative Commons
Vrkljan Anamarija Zrilic, Ana Majić,

Tanja Režić Palaversa

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(2), P. 314 - 314

Published: Feb. 12, 2024

Background and Objectives: The interaction between thyroid SARS-CoV-2 is complex not yet fully understood. This study aimed to identify a predictive value of serum TSH levels on the short-term middle-term outcomes patients hospitalized for COVID-19. Materials Methods: We retrospectively analyzed electronic records (ERs) data COVID-19 March 2020 June 2021 their ERs during outpatient visits, 6–8 weeks post-discharge, in cases known no previous disorder. (length hospital stay, MSCT findings lung involvement, required level oxygen supplementation, admission ICU, death) after 6 8 post-discharge (MSCT involvement) were analyzed. Results: There 580 included: 302 males 278 females, average age 66.39 ± 13.31 years, with disease (TSH mean 1.16 1.8; median 0.80; higher than 6.0 mIU/L included). Higher was observed less severe associated significantly SpO2 hospitalization. Patients who overall more supplementation or HFOT, mechanical ventilation, frequently admitted ICU often treated corticosteroids had lower those did show these indicators severity. Lower also present non-survivors when compared survivors (all p < 0.01). low hospitalization persistent involvement post-COVID-19 period (p = 0.028). In period, there an overall, statistically significant increase 0.001). Conclusions: Low/suppressed acute may be additional laboratory test that should included prediction unfavorable short- outcomes.

Language: Английский

Citations

0